Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARAMUNE: Nivolumab + Paclitaxel + Ramucirumab in Advanced Gastric and Esophageal Adenocarcinoma
NCT06203600Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2024
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in gastric adenocarcinoma, esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Progression-Free Survival up to 3 years and Overall Survival up to 3 years. Started Jun 2024; status: recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06203600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06203600.